|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||9.12 - 9.14|
|52-week range||9.12 - 9.14|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
What happened Shares of Dynavax Technologies (NASDAQ: DVAX) were up by 3.6% as of 11:38 a.m. EDT on Thursday after having gained as much as 6.9% earlier in the session. The stock's rise came following the company's announcement that it has signed a deal with Bavarian Nordic to market and distribute its hepatitis B vaccine Heplisav B in Germany.